Breast cancer recurrence following active treatment: Determining its incidence in the NSW population

Public Health Research and Practice

Volumn 26, Issue 1, 2016, Pages

  Kemp Casey, Anna ^a,d   Roughead, Elizabeth E ^b   Saunders, Christobel ^a   Boyle, Frances ^c   Lopez, Derrick ^a   Bulsara, Max ^a   Preen, David B ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF NOTRE DAME   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST NEOPLASMS; FACTUAL DATABASE; FEMALE; HUMAN; INCIDENCE; NEW SOUTH WALES; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; TUMOR RECURRENCE;

BREAST NEOPLASMS; DATABASES, FACTUAL; FEMALE; HUMANS; INCIDENCE; NEOPLASM RECURRENCE, LOCAL; NEW SOUTH WALES; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES;

EID: 84994169044     PISSN: None     EISSN: 22042091     Source Type: Journal    
DOI: 10.17061/phrp2611607     Document Type: Article

References (34)

1. Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, et al. SEER cancer statistics review, 1975-2010. Bethesda, MD: National Cancer Institute; 2013 [cited 2015 Aug 13]. Available from: www. seer.cancer.gov/archive/csr/1975-2010/results-merged/sect-04-breast.pdf
2. Cancer Australia. Shared follow-up care. Sydney: Cancer Australia; 2015 [cited 2015 Oct 16]. Available from: www. canceraustralia.gov.au/affected-cancer/cancer-types/breast-cancer/life-after-breast-cancer/shared-follow-care
3. American Cancer Society. When cancer comes back: cancer recurrence. Atlanta, GA: American Cancer Society; 2015 [cited 2015 Oct 16]. Available from: www.cancer.org/acs/groups/cid/documents/webcontent/002947-pdf.pdf
4. Rack B, Janni W, Gerber B, Strobl B, Schindlbeck C, Klanner E, et al. Patients with recurrent breast cancer: does the primary axillary lymph node status predict more aggressive tumor progression? Breast Cancer Res Treat. 2003;82(2):83-92.
5. Hess KR, Esteva FJ. Effect of HER2 status on distant recurrence in early stage breast cancer. Breast Cancer Res Treat. 2013;137(2):449-55.
6. Yu K, Wu J, Shen Z, Shao Z. Hazard of breast cancer-specifc mortality among women with estrogen receptor-positive breast cancer after fve years from diagnosis: implication for extended endocrine therapy. J Clin Endocrinol Metab. 2012;97(12):E2201-9.
7. Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in early-stage breast cancer. Oncologist. 2004;9(6):606-16.
8. Hodgkinson K, Butow P, Hunt G, Pendlebury S, Hobbs K, Wain G. Breast cancer survivors' supportive care needs 2-10 years after diagnosis. Support Care Cancer. 2007;15:(5)515-23.
9. Lord S, Marinovich M, Patterson J, Wilcken N, Kiely B, Gebski V, et al. Incidence of metastatic breast cancer in an Australian population-based cohort of women with non-metastatic breast cancer at diagnosis. Med J Aust. 2012;196(11):688-92.
10. Stokes M, Thompson D, Montoya EL, Weinstein MC, Winer EP, Earle CC. Ten-year survival and cost following breast cancer recurrence: Estimates from SEER-Medicare data. Value Health. 2008;11(2):213-20.
11. iSource National Breast Cancer Centre Advanced Breast Cancer Working Group. Clinical practice guidelines for the management of advanced breast cancer. Canberra: National Health and Medical Research Council, Commonwealth of Australia; 2001 [cited 2015 Oct 29]. Available from: www.nhmrc.gov.au/-fles-nhmrc/publications/attachments/cp76-management-advanced- breast-cancer-131223.pdf
12. NSW Central Cancer Registry. NSW Central Cancer Registry data dictionary. Sydney: Cancer Institute NSW; 2014 [cited 2015 Jun 26]. Available from: www. cancerinstitute.org.au/media/165425/nsw-central-cancer-registry-data-dictionary.pdf
13. Ministry of Health, NSW. Cancer Registry-notifying cancer cases to the NSW Central Cancer Registry. Sydney: NSW Health; 2009 [cited 2015 Jun 26]. Available from: www0.health.nsw.gov.au/policies/pd/2009/pdf/PD2009-012.pdf
14. Northern Territory Cancer Registry. Northern Territory Cancer Register: data collection, analysis and reporting procedures. Darwin: NT Department of Health and Community Services; 2004 [cited 2015 Jun 26]. Available from: digitallibrary.health.nt.gov.au/prodjspui/bitstream/10137/61/1/cancer-register-data-collection.pdf
15. Queensland Cancer Registry. Queensland Cancer Registry instruction manual for notifying cancer: HBCIS hospitals. Brisbane: Cancer Council Queensland; 2009 [cited2015 Jun 26]. Available from: www.cancerqld. org.au/page/Research-statistics/queensland-cancer- registry/QCR-public-hospital-notifcations/
16. Queensland Cancer Registry. Access to data for researchers. Brisbane: Cancer Council Queensland [cited 2015 Jun 26]. Available from: www.cancerqld.org. au/page/research-statistics/queensland-cancer-registry/
17. Population Health Research Network. Brisbane: the Network; c2011 [cited 2015 Jun 26]. Data collections available: South Australia; [about 9 screens]. Available from: www.phrn.org.au/for-researchers/data-collections-available/south-australia/
18. Menzies Institute for Medical Research. Tasmanian Cancer Registry. Hobart: University of Tasmania; 2008 [cited 2015 Jun 26]. Available from: www.menzies.utas. edu.au/article.php?Doo=ContentView&id=920
19. Western Australian Government. Health (Western Australian Cancer Register) regulations. Perth: Government of Western Australia; 2011 [cited 2015 Jun 25]. Available from: www.health.wa.gov.au/wacr/docs/CurrentRegulations-Detail.pdf
20. Australian Government Department of Health and Ageing. Schedule of pharmaceutical benefts, 1 April-30 April 2010. Canberra: Australian Government; 2010 [cited 2010 Aug 12]. Available from: www.pbs.gov.au/publication/schedule/2010/2010-04-01-general-schedule.pdf
21. 45 and Up Study Collaborators, Banks E, Redman S, Jorm L, Armstrong B, Bauman A, et al. Cohort profle: The 45 and Up Study. Int J Epidemiol. 2008;37(5):941-7.
22. Banks E, Jorm L, Wutzke S. The 45 and Up Study: fostering population health research in NSW. N S W Public Health Bull. 2011;22(2):1516.
23. Sax Institute. Sydney: The Institute. Researcher toolkit; c2005 [cited 2013 Oct 31]. Available from: www. saxinstitute.org.au/our-work/45-up-study/for-researchers/
24. Mealing N, Banks E, Jorm L, Steel D, Clements M, Rogers KD. Investigation of relative risk estimates from studies of the same population with contrasting response rates and designs. BMC Med Res Methodol. 2010;10:26.
25. CHeReL: Centre for Health Record Linkage. Sydney: CHeReL; c2011 [cited 2012 Jun 6]. Available from: www.cherel.org.au
26. Centre for Health Record Linkage. Sydney: The Centre; c2011 [cited 2015 Oct 16]. Quality assurance; [about 4 screens]. Available from: www.cherel.org.au/quality-assurance
27. Pharmaceutical Benefts Scheme. Canberra: Australian Government Department of Health; 2006 Oct 1 [cited 2015 Jun 24]. Listing of Herceptin on the PBS Canberra; [about 4 screens]. Available from: www.pbs.gov.au/info/news/2006/10/listing-of-herceptin
28. Anderson WF, Chen BE, Jatoi I, Rosenberg PS. Effects of estrogen receptor expression and histopathology on annual hazard rates of death from breast cancer. Breast Cancer Res Treat. 2006;100:121-6.
29. Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer. 2007;7:153.
30. Kemp A, Preen DB, Saunders C, Boyle F, Bulsara M, Malacova E, Roughead EE. Early discontinuation of endocrine therapy for breast cancer: who is at risk in clinical practice? Springerplus. 2014;3:282.
31. Earle CC, Nattinger AB, Potosky AL, Lang K, Mallick R, Berger M, Warren JL. Identifying cancer relapse using SEER-Medicare data. Med Care. 2002;40(8 Suppl):IV-75-81.
32. Willett WC, Blott WJ, Colditz GA, Folsom AR, Henderson BE, Stampfer MJ. Merging and emerging cohorts. Not worth the wait. Nature. 2007;445(7125):257-8.
33. Australian Institute of Health and Welfare, Cancer Australia. Breast cancer in Australia: an overview. Canberra: Australian Institute of Health and Welfare; 2012 [cited 2015 Oct 29]. Available from: www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=10737423006
34. Nixon AJ, Neuberg D, Hayes DF, Gelman R, Connolly JL, Schnitt S, et al. Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Onc. 1994;12(5):888-94.